Date: 2012-06-04
Type of information: Presentation of results at a congress
phase: 2
Announcement: presentation of results at the American Society of Clinical Oncology (ASCO) annual meeting, in Chicago
Company: MolMed (Italy)
Product: NGR-hTNF
Action
mechanism: protein. NGR-hTNF is a vascular targeting agent with unique mode of action, and a first-in-class compound in the class of peptide/cytokine complexes able to selectively target the tumour vasculature. It consists of a tumour homing peptide (NGR) that selectively binds tumour blood vessels, fused to the human Tumour Necrosis Factor (TNF). NGR- hTNF is undergoing clinical development both as monotherapy and in combination therapy, in a total of seven indications.
Disease: non-small cell lung cancer (NSCLC)
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: MolMed has presented at the 48th ASCO Annual meeting initial results on the survival of a randomised phase II trial of NGR-hTNF in combination with standard chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC) (ASCO poster 7581). This ongoing trial is assessing two chemotherapy regimens with and without NGR-hTNF in 120 patients with either non-squamous or squamous histology. In patients with squamous histology, clinical benefits are observed in combination with NGR-hTNF compared to chemotherapy alone with a 30% relative reduction in the risk of tumour progression and a 50% relative reduction in the risk of death. The value of these results is reinforced by the lack of bleeding events that have severely hampered the use of antiangiogenic drugs.
